Does choice of antidiabetes therapy influence macrovascular outcomes?

Current Diabetes Reports

Volumn 10, Issue 1, 2010, Pages 24-31

  Zarich, Stuart W ^a  

^a BRIDGEPORT HOSPITAL   (United States)

Author keywords

Antidiabetic medications; Cardiovascular disease; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; METFORMIN; NATEGLINIDE; PHENFORMIN; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ANGIONEUROTIC EDEMA; BODY WEIGHT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DIARRHEA; DRUG CHOICE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPOGLYCEMIA; IN-STENT RESTENOSIS; INSULIN TREATMENT; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; REVIEW; RISK REDUCTION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; VOMITING; WEIGHT GAIN;

BLOOD VESSELS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 77249102005     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0083-9     Document Type: Review

References (57)

1. J Stamler O Vaccaro JD Neaton D Wentworth 1993 Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Invention Trial Diabetes Care 16 434 444 10.2337/diacare.16.2.434 1:STN:280:DyaK3s7mtFyrtQ%3D%3D 8432214
2. Mak KH, Moliterno DJ, Granger CB, et al.: Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997, 30:171-179.
3. SM Haffner S Lehto T Rönnemaa, et al. 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 229 234 10.1056/NEJM199807233390404 1:STN:280:DyaK1czivVKgsg%3D%3D 9673301 (Pubitemid 28350165)
4. S Wild G Roglic A Green, et al. 2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 1047 1053 10.2337/diacare.27.5.1047 15111519 (Pubitemid 38579764)
5. J Buse HN Ginsberg GL Bakris, et al. 2007 Primary prevention of cardiovascular disease in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association Circulation 115 114 126 10.1161/CIRCULATIONAHA.106.179294 17192512 (Pubitemid 46058619)
6. E Selvin S Marinopoulos G Berkenblit, et al. 2004 Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus Ann Intern Med 141 421 431 1:CAS:528:DC%2BD2cXos1Cjtrk%3D 15381515
7. N Feinglos A Bethel 1999 Therapy of type 2 diabetes, cardiovascular death, and the UGDP Am Heart J 138 S346 S352 1:STN:280:DC%2BD3c%2FgslGhsA%3D%3D 10539796
8. C Schotborgh A Wilde 1997 Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients Cardiovasc Res 34 73 80 10.1016/S0008-6363(97)00036-9 1:CAS:528:DyaK2sXktlOlsbo%3D 9217875 (Pubitemid 27261915)
9. Smits P, Bijlstra P, Russel F, et al:. Cardiovascular effects of sulphonylurea derivatives. Diab Res Clin Pract 1996, 31(Suppl):S55-S59.
10. H Klepzig G Kober C Matter, et al. 1999 Sulfonylureas and ischaemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide Eur Heart J 20 439 444 10.1053/euhj.1998.1242 1:CAS:528:DyaK1MXisVejs7o%3D 10213347 (Pubitemid 29116540)
11. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837-853. (Published erratum appears in Lancet 1999, 354:602.)
12. DM Nathan JB Buse MB Davidson, et al. 2009 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of diabetes Diabetes Care 32 193 203 10.2337/dc08-9025 1:CAS:528:DC%2BD1MXhs1Gns78%3D 18945920
13. IM Stratton AI Adler HA Neil, et al. 2000 Association of glycaemia with microvascular and macrovascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 405 412 10.1136/bmj.321.7258.405 1:STN:280:DC%2BD3cvisFWnsg%3D%3D 10938048
14. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854-865. (Published erratum appears in Lancet 1998, 352:1557.)
15. E Selvin S Bolen HC Yeh, et al. 2008 Cardiovascular outcomes in trials of oral diabetic medications: a systematic review Arch Intern Med 168 2070 2080 10.1001/archinte.168.19.2070 18955635
16. S Kahn S Haffner M Heise, et al. 2006 Glycemic durability of rosiglitazone, metformin or glyburide monotherapy N Engl J Med 356 2427 2443 10.1056/NEJMoa066224 (Pubitemid 44903747)
17. A Rao N Kuhayiya K Reynolds, et al. 2008 Is the combination of sulfonylurea and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? Diabetes Care 31 1672 1678 10.2337/dc08-0167 18458139
18. M Cook C Girman P Stein, et al. 2005 Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes Diabetes Care 28 995 1000 10.2337/diacare.28.5.995 1:CAS:528:DC%2BD2MXksF2hu74%3D 15855556 (Pubitemid 40616602)
19. R Holman S Paul A Bethel, et al. 2008 A ten-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577 1589 10.1056/NEJMoa0806470 1:CAS:528:DC%2BD1cXht1Wgt7nK 18784090 Ten-year results of the UKPDS confirm a long-term cardiovascular benefit of intensive glucose lowering with conventional agents (SU, insulin, and metformin). This is consistent with prior studies suggesting that glucose control may take many years before a benefit is seen compared with the effects of lipid lowering.
20. J Shaw R Wilmot E Kilpatrick 2007 Establishing pragmatic estimated GFR thresholds to guide metformin prescribing Diabetes Med 24 1160 1163 10.1111/j.1464-5491.2007.02221.x 1:STN:280:DC%2BD2srmslSksQ%3D%3D (Pubitemid 47437878)
21. D Eurich S Majumbar F McAlister, et al. 2005 Improved clinical outcomes associated with metformin in patients with diabetes and heart failure Diabetes Care 28 2345 2351 10.2337/diacare.28.10.2345 1:CAS:528:DC%2BD2MXhtFGqtr3P 16186261 (Pubitemid 41384275)
22. FA Masoudi SE Inzucchi Y Wang, et al. 2005 Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure Circulation 111 583 590 10.1161/01.CIR.0000154542.13412.B1 1:CAS:528:DC%2BD2MXovFKhsw%3D%3D 15699279 (Pubitemid 40216485)
23. AA Parulkar ML Pendergrass R Granda-Ayala, et al. 2001 Non-hypoglycemic effects of thiazolidinediones Ann Intern Med 134 61 71 1:CAS:528: DC%2BD3MXltVSlsA%3D%3D 11187421
24. Yue Tl TL, Chen J, Bao W, et al.: In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001, 104:2588-2594.
25. T Shiomi H Tsutsui S Hayashidani, et al. 2002 Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 106 3126 3132 10.1161/01.CIR.0000039346.31538.2C 12473562 (Pubitemid 35440299)
26. WH Sauer JA Berlin SE Kimmel 2002 Thiazolidinediones and prevention of myocardial infarction in patients with type 2 diabetes Circulation 106 2777
27. T Takagi A Yamamuro K Tamita, et al. 2003 Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study Am Heart J 146 E5 10.1016/S0002-8703(03)00146-7 12891212
28. D Choi SK Kim SH Choi, et al. 2004 Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes Diabetes Care 27 2654 2660 10.2337/diacare.27.11.2654 1:CAS:528: DC%2BD2cXhtVKis7zP 15505001 (Pubitemid 39441466)
29. T Mazzone PM Meyer SB Feinstein, et al. 2006 Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2572 2581 10.1001/jama.296.21.joc60158 1:CAS:528:DC%2BD28Xht12lsbbM 17101640 (Pubitemid 44903861)
30. JS Sidhu Z Kaposzta HS Markus JC Kaski 2004 Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus Arterioscler Thromb Vasc Biol 24 930 934 10.1161/01.ATV.0000124890.40436.77 1:CAS:528:DC%2BD2cXjsFSnur8%3D 15001452 (Pubitemid 38620874)
31. SE Nissen SJ Nicholls K Wolski, et al. 2008 Comparison of pioglitazone vs glimepiride on progression of atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized trial JAMA 299 1561 1573 10.1001/jama.299.13.1561 1:CAS:528:DC%2BD1cXktlSqtbg%3D 18378631
32. B Charbonnel J Dormandy E Erdmann, et al. 2004 The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diabetes Care 27 1647 1653 10.2337/diacare.27.7.1647 15220241 (Pubitemid 38857439)
33. DJ Betteridge RA DeFronzo RJ Chilton 2008 PROactive: time for a critical appraisal Eur Heart J 29 969 983 10.1093/eurheartj/ehn114 18375395 (Pubitemid 351844691)
34. S Nissen K Wolski 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457 2471 10.1056/NEJMoa072761 1:CAS:528:DC%2BD2sXms1SisrY%3D 17517853 (Pubitemid 46919772)
35. GA Diamond L Bax S Kaul 2007 Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death Ann Intern Med 147 578 581 17679700
36. S Singh YK Loke CD Furberg 2007 Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis JAMA 298 1189 1195 10.1001/jama.298.10.1189 1:CAS:528:DC%2BD2sXhtVGmtL3K 17848653 (Pubitemid 47403105)
37. AM Lincoff K Wolski SJ Nicholls SE Nissen 2007 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 1180 1188 10.1001/jama.298.10.1180 1:CAS:528:DC%2BD2sXhtVGmtL3J 17848652 (Pubitemid 47403104)
38. PD Home SJ Pocock H Beck-Nielsen, et al. 2005 Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol Diabetologia 48 1726 1735 10.1007/s00125-005-1869-1 1:CAS:528:DC%2BD2MXhtVSqt7fK 16025252 (Pubitemid 41317825)
39. PD Home SJ Pocock H Beck-Nielsen, et al. 2009 Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes: a multicentre, randomized, open-label trial (RECORD) Lancet 373 2125 2135 10.1016/S0140-6736(09)60953-3 1:CAS:528:DC%2BD1MXnsFSis78%3D 19501900 The final results of the RECORD trial meet the criteria of noninferiority with rosiglitazone compared with SU and metformin. No increased risk for CV events was seen, but event rates were too low to be conclusive. Rosiglitazone was associated with improved glycemic control compared with conventional therapy, similar to the findings in the ADOPT (A Diabetes Outcome Progression Trial) trial.
40. RM Lago PP Singh RW Nesto 2007 Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials Lancet 370 1129 1136 10.1016/S0140-6736(07)61514-1 1:CAS:528:DC%2BD2sXhtFSntLzO 17905165 (Pubitemid 47464583)
41. W Duckworth 2009 Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 129 139 10.1056/NEJMoa0808431 1:CAS:528:DC%2BD1MXnsFWkug%3D%3D 19092145
42. Action to Control Cardiovascular Risk in Diabetes Study Group 2008 Effects of intensive blood glucose lowering in type 2 diabetes N Engl J Med 358 2545 2559 10.1056/NEJMoa0802743 (Pubitemid 351831356)
43. •• BARI 2D Study Group: A randomized trial of therapies for type 2 diabetes and coronary disease. N Engl J Med 2009, 360:2503-2515. The results of the BARI-2D trials show that a strategy of insulin-sensitizing compared with insulin-providing therapy is associated with better glycemic control, higher HDL levels, less weight gain, and fewer hypoglycemic events. CV outcomes were similar between the two strategies in T2DM patients with stable coronary artery disease.
44. R Holman R Retnakaran A Farner R Stevens 2006 PROactive study Lancet 367 25 26 10.1016/S0140-6736(06)67914-2 1:STN:280:DC%2BD28%2FhtlyrtA%3D%3D 16399144 (Pubitemid 43038659)
45. DT Eurich FA McAlister DF Blackburn, et al. 2007 Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review BMJ 335 497 10.1136/bmj.39314.620174.80 1:CAS:528:DC%2BD2sXhtFOntr%2FE 17761999 (Pubitemid 47401611)
46. HJ Dargie PR Hildebrandt GA Riegger, et al. 2007 A randomized placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure J Am Coll Cardiol 49 1694 1704 10.1016/j.jacc.2006.10.077 (Pubitemid 46589926)
47. JL Chaisson RG Josse R Gomis, et al. 2003 Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 486 494 10.1001/jama.290.4.486 (Pubitemid 37430502)
48. J Rosenstock D Hassman R Madder, et al. 2004 Repaglinide versus nateglinide monotherapy: a randomized, multicenter study Diabetes Care 27 1265 1270 10.2337/diacare.27.6.1265 1:CAS:528:DC%2BD2cXlt1yltb0%3D 15161773 (Pubitemid 38679968)
49. K Ban MH Noyan-Ashraf J Hoefer, et al. 2008 Cardioprotective and vasodilatory actions of glucagons-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2340 2350 10.1161/CIRCULATIONAHA.107.739938 1:CAS:528: DC%2BD1cXltFyltrY%3D 18427132 (Pubitemid 351653542)
50. P Dandona P Mohanty A Chaudhuri, et al. 2005 Insulin infusion in acute illness J Clin Invest 115 2069 2072 10.1172/JCI26045 1:CAS:528: DC%2BD2MXntFCmt7Y%3D 16075050 (Pubitemid 41134145)
51. M Anselmino J Ohrvik K Malmberg, et al. 2008 Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart Eur Heart J 29 177 184 10.1093/eurheartj/ehm519 18156611
52. LG Mellvin K Malmberg A Norhammar, et al. 2008 The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial Eur Heart J 29 166 176 10.1093/eurheartj/ehm518
53. Malmberg K: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997, 314:1512-1515.
54. DM Nathan PA Cleary JY Backlund, et al. 2005 Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes mellitus N Engl J Med 353 2643 2653 10.1056/NEJMoa052187 16371630 (Pubitemid 41817713)
55. Origin Trial Investigators 2008 Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention) Am Heart J 155 26 32 1:STN:280: DC%2BD2sjks1Sgtg%3D%3D 18082485
56. R Holman A Farmer M Davies, et al. 2009 Three-year efficacy of complex insulin regimens in type 2 diabetes N Engl J Med 361 1736 1747 10.1056/NEJMoa0905479 1:CAS:528:DC%2BD1MXhtlWqsL7E 19850703
57. I Raz P Wilson K Strojek, et al. 2009 Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial Diabetes Care 32 381 386 10.2337/dc08-1671 1:CAS:528:DC%2BD1MXjvVyqsbk%3D 19246588